181 related articles for article (PubMed ID: 26866009)
1. Human Leukocyte Antigen Alleles and Cytomegalovirus Infection After Renal Transplantation.
Futohi F; Saber A; Nemati E; Einollahi B; Rostami Z
Nephrourol Mon; 2015 Nov; 7(6):e31635. PubMed ID: 26866009
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?
Wong G; Chakera A; Chapman JR; Chadban SC; Pilmore H; Craig JC; Lim WH
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27860123
[TBL] [Abstract][Full Text] [Related]
3. Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection.
Retière C; Lesimple B; Lepelletier D; Bignon JD; Hallet MM; Imbert-Marcille BM
Transplantation; 2003 Jan; 75(1):161-5. PubMed ID: 12544891
[TBL] [Abstract][Full Text] [Related]
4. Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation.
Fan J; Meng XQ; Yang MF; Zhou L; Chen XM; Hu MJ; Fan WW; Ma WH; Li LJ
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):34-8. PubMed ID: 16481279
[TBL] [Abstract][Full Text] [Related]
5. Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as Genetic Markers for Stratifying the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska-Jakubowicz A; Gozdowska J; Ciszek M; Pazik J; Ostaszewska A; Kosieradzki M; Nowak J; Durlik M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30696053
[TBL] [Abstract][Full Text] [Related]
6. Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation.
Aldridge RW; Mattes FM; Rolando N; Rolles K; Smith C; Shirling G; Atkinson C; Burroughs AK; Milne RS; Emery VC; Griffiths PD
Transpl Infect Dis; 2015 Feb; 17(1):25-32. PubMed ID: 25572799
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection.
Schnitzler MA; Woodward RS; Brennan DC; Spitznagel EL; Dunagan WC; Bailey TC
Surgery; 1997 May; 121(5):563-8. PubMed ID: 9142156
[TBL] [Abstract][Full Text] [Related]
8. Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from northwestern China.
Jin ZK; Xu CX; Tian PX; Xue WJ; Ding XM; Zheng J; Ding CG; Ge GQ; Mao TC; Lin Y
Transpl Immunol; 2012 Oct; 27(2-3):69-74. PubMed ID: 22750489
[TBL] [Abstract][Full Text] [Related]
9. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D Levels After Kidney Transplantation and the Risk of Cytomegalovirus Infection.
Saber A; Fotuhi F; Rostami Z; Einollahi B; Nemati E
Nephrourol Mon; 2015 Nov; 7(6):e29677. PubMed ID: 26866004
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
[TBL] [Abstract][Full Text] [Related]
13. Recipient HLA-G +3142 CC Genotype and Concentrations of Soluble HLA-G Impact on Occurrence of CMV Infection after Living-Donor Kidney Transplantation.
Guberina H; Tomoya Michita R; Dolff S; Bienholz A; Trilling M; Heinemann FM; Horn PA; Kribben A; Witzke O; Rebmann V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29113092
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Infection following Kidney Transplantation: a Multicenter Study of 3065 Cases.
Einollahi B
Int J Organ Transplant Med; 2012; 3(2):74-8. PubMed ID: 25013626
[TBL] [Abstract][Full Text] [Related]
15. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
16. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
17. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
